newsfilter
← Latest News
ACCESS Newswire·

Novamind Granted DEA Licenses for Psilocybin Research

Licenses a key step in hosting contracted clinical trials for Schedule 1 controlled substances TORONTO, ON / ACCESSWIRE / October 13, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company spec